Followers | 1320 |
Posts | 26908 |
Boards Moderated | 6 |
Alias Born | 12/10/2012 |
Wednesday, September 20, 2023 9:46:40 AM
OKkkkkkkkkkkkkkkkkkkk.......... lets gooooooooooooooo
GO $SPRY
Recent SPRY News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/16/2024 11:52:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/10/2024 11:01:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/09/2024 10:59:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 08:08:39 PM
- ARS Pharmaceuticals Highlights neffy Regulatory Progress and Reports First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/09/2024 08:05:00 PM
- ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand • GlobeNewswire Inc. • 04/30/2024 01:01:00 PM
- ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy® (Epinephrine Nasal Spray) • GlobeNewswire Inc. • 04/03/2024 01:01:00 PM
- ARS Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 03/21/2024 08:05:00 PM
- ARS Pharmaceuticals Reviews Recent Clinical Updates and Commercial Opportunity at neffy® Investor Day • GlobeNewswire Inc. • 03/07/2024 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 05:56:52 PM
- ARS Pharmaceuticals to Participate in the Leerink Partners Global Biopharma Conference 2024 • GlobeNewswire Inc. • 03/06/2024 02:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/02/2024 01:21:36 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 02:08:51 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/26/2024 05:08:35 PM
- ARS Pharmaceuticals announces neffy® meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical study • GlobeNewswire Inc. • 02/26/2024 02:01:00 PM
- ARS Pharmaceuticals to Host Virtual neffy® Investor Day on March 7, 2024 • GlobeNewswire Inc. • 02/22/2024 02:01:00 PM
- ARS Pharma Announces Favorable Topline Results from Repeat Dosing Study of neffy® (Epinephrine Nasal Spray) Under Nasal Allergen Challenge Conditions, Readies Data for Response to FDA’s Complete Response Letter • GlobeNewswire Inc. • 02/20/2024 02:01:00 PM
- ARS Pharmaceuticals to Present Positive Clinical Efficacy Data for neffy® (epinephrine nasal spray) at 2024 AAAAI Annual Meeting • GlobeNewswire Inc. • 02/05/2024 02:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 09:47:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 09:45:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 09:41:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 09:39:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:02:29 PM
- ARS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 11/09/2023 09:00:00 PM
- ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis • GlobeNewswire Inc. • 11/09/2023 04:02:36 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM